Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novo reports weakening diabetes sales in China

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported earnings and said China sales declined 6% in 2Q15 compared to 2Q14, as measured in local currencies. On a conference call, CEO

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE